Detalhe da pesquisa
1.
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Cell;
186(6): 1127-1143.e18, 2023 03 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36931243
2.
Exhausted intratumoral Vδ2- γδ T cells in human kidney cancer retain effector function.
Nat Immunol;
24(4): 612-624, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36928415
3.
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
Cell;
181(7): 1612-1625.e13, 2020 06 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32497499
4.
Tissue Determinants of Human NK Cell Development, Function, and Residence.
Cell;
180(4): 749-763.e13, 2020 02 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32059780
5.
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Cell;
177(2): 414-427.e13, 2019 04 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30951669
6.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell;
174(3): 758-769.e9, 2018 07 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30033370
7.
TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments.
Immunity;
56(12): 2682-2698.e9, 2023 Dec 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38091950
8.
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Cell;
168(3): 487-502.e15, 2017 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28111070
9.
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.
Immunity;
54(12): 2701-2711, 2021 12 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34910940
10.
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Immunity;
50(2): 477-492.e8, 2019 02 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30737146
11.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell;
175(3): 889, 2018 10 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30340047
12.
Immunity in the Time of Metastases.
Immunity;
49(6): 1002-1003, 2018 12 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30566878
13.
Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
Clin Gastroenterol Hepatol;
2024 Feb 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38401693
14.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature;
554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29443960
15.
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
Lancet Oncol;
24(11): 1266-1276, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37922930
16.
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
Br J Cancer;
129(2): 291-300, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37208512
17.
Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis.
J Natl Compr Canc Netw;
21(6): 617-626.e3, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37308118
18.
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Oncologist;
27(6): 453-461, 2022 06 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35373299
19.
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
Cancer Immunol Immunother;
70(7): 2095-2102, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33420629
20.
Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.
Cancer Immunol Immunother;
70(10): 3031-3040, 2021 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33864502